Stock Events

Stock Events

Inhibrx Biosciences 

0
20
+$0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

19AugExpected
Q3 2025
Q1 2026
Q2 2026
-2.28
-2.08
-1.88
-1.68
Expected EPS
-2.28
Actual EPS
N/A

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.8B
Regeneron Pharmaceuticals competes in the biotechnology field focusing on immunology and oncology, similar to Inhibrx's focus areas.
AMGEN
AMGN
Mkt Cap208.49B
Amgen operates in the same biopharmaceutical sector, developing therapies in areas like oncology, which overlaps with Inhibrx's pipeline.
Gilead Sciences
GILD
Mkt Cap186.13B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas including oncology, directly competing with Inhibrx.
Bristol-Myers Squibb
BMY
Mkt Cap128.81B
Bristol Myers Squibb offers a range of cancer treatments, competing in the oncology space with Inhibrx.
Merck
MRK
Mkt Cap362.35B
Merck & Co., Inc. is a global healthcare company that produces cancer drugs and vaccines, making it a competitor in the oncology field.
Pfizer
PFE
Mkt Cap157.65B
Pfizer is a large pharmaceutical company with a broad portfolio that includes oncology and immunology drugs, competing with Inhibrx.
Novartis
NVS
Mkt Cap266.8B
Novartis AG focuses on patented medicines for a range of diseases, including cancer, directly competing with Inhibrx's research and development in oncology.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG specializes in biotechnology products for oncology, among other areas, making it a competitor in the same field as Inhibrx.
Astrazeneca
AZN
Mkt Cap257.57B
AstraZeneca PLC operates in various therapeutic areas, including oncology, competing with Inhibrx in the development of cancer treatments.

About

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Show more...
CEO
Mark Lappe
Employees
110
Country
United States

Listings

XNAS
US
INBX
BOATS
BOATS
INBX.BOATS
NASDAQ
US
INXB V

0 Comments

Share your thoughts

FAQ

What is Inhibrx Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Inhibrx Biosciences stocks are traded under the ticker INXB V.
How many employees does Inhibrx Biosciences have?▼
As of September 22, 2026, the company has 110 employees.
In which sector is Inhibrx Biosciences located?▼
Inhibrx Biosciences operates in the Health & Wellness sector.
When did Inhibrx Biosciences complete a stock split?▼
Inhibrx Biosciences has not had any recent stock splits.
Where is Inhibrx Biosciences headquartered?▼
Inhibrx Biosciences is headquartered in La Jolla, United States.